CHRS - Coherus BioSciences, Inc.
After hours:
Chart Events
Relative Strength Index (RSI)
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 4.0500 |
| Open | 4.2500 |
| Bid | 4.4500 x 2200 |
| Ask | 4.4800 x 1000 |
| Day's Range | 4.0636 - 4.5050 |
| 52 Week Range | 3.6000 - 14.1100 |
| Volume | |
| Avg. Volume | 1,844,201 |
| Market Cap | 418.67M |
| Beta (5Y Monthly) | 0.95 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.4000 |
| Earnings Date | Aug 02, 2023 - Aug 07, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 15.75 |
Fair Value
Related Research
- Reuters
UPDATE 2-Coherus BioSciences to launch Humira biosimilar at 85% discount
Coherus BioSciences Inc said on Thursday it plans to launch a biosimilar of AbbVie Inc's Humira in July at a list price of $995 per carton, representing a discount of about 85% from the blockbuster arthritis drug. The annual cost of the biosimilar, branded as Yusimry, will be around $13,000, compared with $90,000 for Humira, Coherus said. Coherus has also partnered with Billionaire entrepreneur Mark Cuban's pharmaceuticals startup to sell the biosimilar at $569.27 plus dispensing and shipping fees.
GlobeNewswireMark Cuban Cost Plus Drug Company joins forces with Coherus to make YUSIMRY™, a HUMIRA® biosimilar, available to patients
– YUSIMRY™ (adalimumab-aqvh) will be the first biologic product offered by the Mark Cuban Cost Plus Drug Company – – YUSIMRY will be available on costplusdrugs.com for $569.27 plus dispensing and shipping fees – DALLAS, Texas and REDWOOD CITY, Calif., June 01, 2023 (GLOBE NEWSWIRE) -- Mark Cuban Cost Plus Drug Company, PBC (“Cost Plus Drugs” or “Mark Cuban Cost Plus Drug Company”) and Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced plans to offer Mark Cuban Cost Plus Drug Co
- GlobeNewswire
Coherus Announces Industry-Wide Lowest List Price for Adalimumab Biosimilar YUSIMRY™ (adalimumab-aqvh) Launching in July 2023
List price of $995 per carton for two 40 mg/0.8 mL autoinjectorsREDWOOD CITY, Calif., June 01, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that the company plans to launch YUSIMRY™ (adalimumab-aqvh) in July 2023* with a list price of $995 per carton (2 x 40 mg/0.8 mL autoinjectors), the lowest price announced to date of any adalimumab offering in the United States. With Humira® currently priced at $6,922 per carton of two autoinjectors, the YUSIM
- Reuters
UPDATE 1-FDA flags issues at Coherus partner's China manufacturing site for cancer drug
Coherus BioSciences Inc said on Wednesday that the U.S. Food and Drug Administration (FDA) flagged three observations at its partner Shanghai Junshi Biosciences Ltd's manufacturing site in China for its experimental cancer drug. The company said it believed that the observations received are readily addressable and it plans to submit its response to the FDA in early June. The U.S. health regulator delayed its decision on the drug in December, as its team had been unable to travel to China to conduct the required site inspection.
GlobeNewswireCoherus Announces U.S. Launch of UDENYCA® Autoinjector
UDENYCA Autoinjector UDENYCA® Autoinjector is the only pegfilgrastim prefilled autoinjector product presentation available in the U.S. that can be administered either in-office or at-home – UDENYCA® AI is the only pegfilgrastim prefilled autoinjector product presentation available in the U.S. that can be administered either in-office or at-home – – UDENYCA® AI fulfills high unmet need by giving providers a new, innovative option that offers patients greater choice, independence and flexibility –
- GlobeNewswire
Coherus Prices Public Offering of Common Stock
REDWOOD CITY, Calif., May 16, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) today announced the pricing of its underwritten public offering of 11,764,706 shares of its common stock at a price to the public of $4.25 per share. All of the shares of the common stock to be sold in the offering will be offered by Coherus. In addition, Coherus has granted the underwriters a 30-day option to purchase up to an additional 1,764,705 shares of its common stock at the public o
- GlobeNewswire
Coherus Announces Proposed Public Offering of Common Stock
REDWOOD CITY, Calif., May 15, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that it has commenced an underwritten public offering of $50.0 million of shares of its common stock. In addition, Coherus expects to grant the underwriters a 30-day option to purchase up to an additional $7.5 million of shares of its common stock at the public offering price, less the underwriting discount. All of the shares of common stock to be sold in the offering will
Simply Wall St.News Flash: 8 Analysts Think Coherus BioSciences, Inc. (NASDAQ:CHRS) Earnings Are Under Threat
One thing we could say about the analysts on Coherus BioSciences, Inc. ( NASDAQ:CHRS ) - they aren't optimistic, having...
- Thomson Reuters StreetEvents
Q1 2023 Coherus BioSciences Inc Earnings Call
Q1 2023 Coherus BioSciences Inc Earnings Call
ZacksCoherus BioSciences (CHRS) Reports Q1 Loss, Misses Revenue Estimates
Coherus BioSciences (CHRS) delivered earnings and revenue surprises of -22.95% and 36.07%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Coherus BioSciences Reports First Quarter 2023 Financial Results and Business Highlights
– UDENYCA® autoinjector approved and ready for May 2023 launch –– CIMERLI® product-specific Q-code now facilitating electronic reimbursement following April 1 activation –– FDA inspection of toripalimab manufacturing site scheduled for May 2023 –– Toripalimab launch anticipated in Q3 2023, if approved –– YUSIMRY™ ready for planned July 2023 launch –– FDA review of UDENYCA® OBI BLA supplement progressing; launch anticipated in 2023, if approved –– Net product revenue of $32.4 million in the first
- GlobeNewswire
Coherus BioSciences to Present at Upcoming Investor Conferences in May
REDWOOD CITY, Calif., May 04, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus“, Nasdaq: CHRS) today announced that senior management will participate in the following investor conferences: Bank of America Merrill Lynch Global Healthcare 2023 Conference in Las Vegas on Thursday, May 11, 2023; fireside chat at 10:15 a.m. PDTUBS Global Healthcare Conference at UBS NY headquarters on Tuesday, May 23, 2023 for 1x1 meetings only between 8:00 a.m. and 5:00 p.m. EDT An audio webcast of the
- GlobeNewswire
Coherus BioSciences to Report First Quarter 2023 Financial Results on May 8, 2023
REDWOOD CITY, Calif., May 01, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus“, Nasdaq: CHRS) today announced its first quarter 2023 financial results will be released after market close on Monday, May 8, 2023. Starting at 5:00 pm ET on May 8, 2023, Coherus’ management team will host a conference call and webcast to discuss financial results and provide a general business update. A replay of the webcast will be available on http://investors.coherus.com following the conclusion of th
- GlobeNewswire
Coherus and Junshi Biosciences Announce Toripalimab Studies to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
SHANGHAI, China and REDWOOD CITY, Calif., April 27, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) today announced that data presentations of four toripalimab pivotal clinical studies will be presented at the upcoming ASCO Annual Meeting, which is being held from June 2-6, 2023 at McCormick Place in Chicago. Presentations Abstract #6009/Poster #1: “Final Overall Survival Analysi
- Simply Wall St.
Coherus BioSciences, Inc. (NASDAQ:CHRS) Held Back By Insufficient Growth Even After Shares Climb 30%
Those holding Coherus BioSciences, Inc. ( NASDAQ:CHRS ) shares would be relieved that the share price has rebounded 30...
Barrons.comThe FDA Is Resuming Drug Lab Inspections in China. These Biotechs Could Benefit.
China's pandemic-era travel restrictions paused approvals on some new drugs. The end of Zero Covid means the pipeline will reopen.
- Investing.com
6 analyst picks: Lululemon sparkles | Pro Recap
Citi upgraded Lululemon Athletica (NASDAQ:LULU) to Buy from Neutral this morning with a price target of $440.00, up from $350.00, after yesterday's better-than-expected earnings report.
- Simply Wall St.
Investors in Coherus BioSciences (NASDAQ:CHRS) have unfortunately lost 64% over the last three years
If you love investing in stocks you're bound to buy some losers. But the last three years have been particularly tough...
Insider MonkeyCoherus BioSciences, Inc. (NASDAQ:CHRS) Q4 2022 Earnings Call Transcript
Coherus BioSciences, Inc. (NASDAQ:CHRS) Q4 2022 Earnings Call Transcript March 6, 2023 Operator: Thank you for standing by, and welcome to Coherus Biosciences Fourth Quarter and Fiscal Year 2022 Earnings Conference Call. I would now like to hand the call over to SVP, Investor Relations, Marek Ciszewski. Please go ahead. Marek Ciszewski: Thank you, Latif, […]
- Thomson Reuters StreetEvents
Q4 2022 Coherus BioSciences Inc Earnings Call
Q4 2022 Coherus BioSciences Inc Earnings Call
- Zacks
Coherus BioSciences (CHRS) Reports Q4 Loss, Misses Revenue Estimates
Coherus BioSciences (CHRS) delivered earnings and revenue surprises of 6.25% and 0.81%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Coherus BioSciences Reports Fourth Quarter and Full Year 2022 Results
– Net product sales of $45.4 million in the fourth quarter 2022 and $211.0 million in FY 2022 –– FDA is planning the toripalimab manufacturing site inspection in Q2 2023 –– UDENYCA® autoinjector approved by FDA; UDENYCA® on-body injector under review by FDA –– Planning underway for potential 2023 commercial launches of toripalimab, YUSIMRY™, UDENYCA® AI and UDENYCA® OBI –– Conference call today at 5 p.m. ET – REDWOOD CITY, Calif., March 06, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Co
- GlobeNewswire
FDA Approves UDENYCA® Autoinjector
- UDENYCA® is the only pegfilgrastim therapy delivered in a convenient, easy-to-administer prefilled autoinjector to offer in-clinic and at-home administration options for cancer patients undergoing myelosuppressive chemotherapy - - An additional presentation, the UDENYCA® proprietary on-body injector (OBI) device, is under review by the FDA with anticipated approval this year - REDWOOD CITY, Calif., March 06, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today an
- GlobeNewswire
Coherus BioSciences to Present at Upcoming Investor Conferences in March
REDWOOD CITY, Calif., March 01, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus“, Nasdaq: CHRS) today announced that senior management will present at the following investor conferences in March. 43rd Annual Cowen Health Care Conference on Tuesday, March 7th at 2:10 p.m. ETBarclays 2023 Global Healthcare Conference on Tuesday, March 14th at 4:05 p.m. ET Audio webcasts of these presentations will be available on the investors’ page of the Coherus website at http://investors.coherus.c
- GlobeNewswire
Coherus BioSciences to Report Fourth Quarter and Full Year 2022 Financial Results on March 6, 2023
REDWOOD CITY, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus“, Nasdaq: CHRS) today announced that its fourth quarter and full year 2022 financial results will be released after market close on Monday, March 6, 2023. Starting at 5:00 pm ET on March 6, 2023, Coherus’ management team will host a conference call and webcast to discuss financial results and provide a general business update. A replay of the webcast will be available on http://investors.coherus.com follo